MedTrace Logo

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

NCT06512883 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-05-15

No results posted yet for this study

Summary

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Conditions

  • Eosinophilic Granulomatosis With Polyangiitis (EGPA)
  • Hypereosinophilia Syndrome (HES)

Interventions

DRUG

Benralizumab

Benralizumab will be administered as SC injection on Q4W.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-17
Primary Completion
2028-02-21
Completion
2028-04-03
FDA Drug
Yes

Countries

  • United States
  • Brazil
  • Canada
  • France
  • India
  • Israel
  • Mexico
  • Netherlands
  • Poland
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06512883 on ClinicalTrials.gov